GSK remains resilient on tariffs as Q1 sales rise 4%
GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it…
01 May 2025
Novartis to strengthen renal disease portfolio with Regulus
Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal disease offerings. The upfront cash payment represents a significant premium over Regulus' recent stock…
01 May 2025
FDA approves J&J’s Imaavy for generalised myasthenia gravis
Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised myasthenia gravis (gMG), a chronic…
01 May 2025
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US trade tariffs and layoffs at the US Food and Drug…
30 Apr 2025
GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led Phase II trial. The NERO study (NCT05455424) investigated the efficacy…
30 Apr 2025
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with borderline personality disorder (BPD) using new technology. The study will…
30 Apr 2025
Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Pharma companies are looking to shore up manufacturing operations in the US to counter international tariffs, but are also bracing for the impact of cuts to the regulatory and research…